![Erman Akkus: Durable stable/partial response to atezo-beva in Hepatocellular Carcinoma](https://oncodaily.com/pub/uploads/2024/07/5dijQf_m_400x400-1-1-e1720352322737.png)
Photo from Erman Akkus/X
Aug 31, 2024, 17:17
Erman Akkus: Durable stable/partial response to atezo-beva in Hepatocellular Carcinoma
Erman Akkus, Medical Oncology Fellow at Ankara University Faculty of Medicine, shared on X:
“Durable stable/partial response to atezo-beva in Hepatocellular Carcinoma.
Significant proportion of HCC tumors become ghost tumors (radiologically persistent without viable tumor cells)
Durable: PR/SD >6 mo
IMbrave150
•CR, PR, SD: 8.9%, 22.1%, 44.2%
•77.8% of PRs and 28.5% SDs were durable
•Durable response -> better survival
Real-word, resection after atezo-beva
•pCR: 57.7% of PR tumors, 16.7% of SD tumors”
![Erman Akkus: Durable stable/partial response to atezo-beva in Hepatocellular Carcinoma 2 Erman Akkus](https://oncodaily.com/pub/uploads/2024/08/IMG_7363-800x393.jpeg)
Source: Erman Akkus/X
For more posts by Erman Akkus, visit oncodaily.com
AkihikoSoyama
Alan Nicholas
Ann-Lii Cheng
Atsushi Naganuma
cancer
Chang-Tsu Yuan
Chi-Jung Wu
Chien-Huai Chuang
Chih-Hsien Cheng
Chih-Hung Hsu
Chikara Ogawa
Erman Akkus
Etsuro Hatano
Hepatocellular carcinoma (HCC)
Hisashi Kosaka
Hung-Wei Wang
Kun-Ming Rau
Li-Chun Lu
Masaki Kaibori
Masatoshi Kudo
NoriakiNakamura
OncoDaily
Oncology
Po-Ting Lin
Richard S. Finn
Sairy Hernandez
Satoru Kakizaki
Shi-Ming Lin
Shinji Itoh
SusumuEguchi
Takamichi Ishii
Tomoharu Yoshizumi
Tse-Ching Chen
Tsung-Hao Liu
Yi-Hsiang Huang
Ying-Chun Shen
Yung-YehSu
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023